How Has the Uterine Fibroids Treatment Market Evolved Historically and What is its Current Size?
The uterine fibroids treatment market has seen considerable growth due to a variety of factors.
•In the recent past, the uterine fibroids treatment market has experienced remarkable growth. The market is expected to ascend from $4.06 billion in 2024 to $4.44 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.2%.
This growth in the historic timeframe could be linked to the burgeoning number of uterine fibroids cases, advancements in diagnostic methodologies, enhanced awareness and education, impact on life quality, and the development of minimally invasive procedures.
What is the Forecasted Market Size and CAGR for the Uterine Fibroids Treatment Market?
The uterine fibroids treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, it is predicted that the uterine fibroids treatment market will experience significant growth, projected to reach "$6.46 billion by 2029 with a compound annual growth rate (CAGR) of 9.8%.
The significant growth during the forecast period can be ascribed to the advancements in non-invasive therapies, a growing focus on preserving fertility, the emergence of minimally invasive techniques, adoptation of personalized medicine, and a collective push in research and development. Key trends in the forecast period comprise a heightened emphasis on treatments that preserve fertility, the incorporation of imaging technology in treatment strategies, initiatives for increasing awareness and education, individualized treatment plans based on distinctive patient profiles as well as the investigation into promising therapeutic targets.
What Key Factors and Trends are Driving the Growth of the Uterine Fibroids Treatment Market?
The uterine fibroids treatment market is anticipated to grow due to the high occurrence rate of uterine fibroids in women. Uterine fibroids are benign growths that form in the uterus, leading to symptoms like heavy periods, abdominal discomfort, and pressure on bowel or bladder. These fibroids can be dealt with by using treatments that hinder the production of estrogen and progesterone, thereby ceasing menstruation and alleviating anemia. As per a report from the National Centre for Biotechnology Information, a US body affiliated with the National Institutes of Health, published in November 2022, the estimated incidence rates of uterine fibroids vary from 40 to 60% in women below 35 years and from 70 to 80% in women aged over 50. Consequently, the significant prevalence of uterine fibroids among women globally is contributing to the expansion of the uterine fibroids treatment market.
What are the Market Segments in the Uterine Fibroids Treatment Market?
The uterine fibroids treatment market covered in this report is segmented –
1) By Type: Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids
2) By Treatment Type: Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy
3) By End-Users: Hospitals, Ambulatory Surgical Centers, Other End users
Subsegments:
1) By Subserosal Fibroids: Pedunculated Subserosal Fibroids, Non-Pedunculated Subserosal Fibroids
2) By Intramural Fibroids: Small Intramural Fibroids, Large Intramural Fibroids
3) By Submucosal Fibroids: Pedunculated Submucosal Fibroids, Non-Pedunculated Submucosal Fibroids
4) By Pedunculated Fibroids: Subserosal Pedunculated Fibroids, Submucosal Pedunculated Fibroids
Pre-Book The Uterine Fibroids Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Uterine Fibroids Treatment Market?
A notable trend in the uterine fibroid treatment market is product innovation. Firms in this sector are focusing on presenting inventive products to maintain their market stance. Case in point, Kissei Pharmaceutical Co., Ltd., a pharmaceutical firm based in Japan, in September 2024, introduced YSELTY, a treatment for uterine fibroids. The launch signified a substantial stride in women's healthcare as YSELTY, a non-hormonal treatment, offers customised dosage to cater to individual patient requirements, especially for those presenting with severe fibroid symptoms. As it is a GnRH receptor antagonist, YSELTY acts by inhibiting the gonadotropin-releasing hormone at its pituitary receptors, thereby significantly reducing estrogen production and effectively alleviating symptoms like bleeding and pain.
Who Are the Key Players in the Uterine Fibroids Treatment Market?
Major companies operating in the uterine fibroids treatment market include:
• Gynesonics Inc.
• Medtronic plc
• Boston Scientific Corporation
• Karl Storz GmbH
• Pfizer Inc.
• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH
• Insightec Ltd.
• Hologic Inc.
• Obseva SA
• Eli Lilly and Company
• GlaxoSmithKline plc
• Stryker Corporation
• Smith & Nephew plc
• Minerva Surgical Inc.
• Ethicon Inc.
• Cook Medical LLC
• C.R. Bard Inc.
• Biomerics LLC
• Visionsense Corp.
• Halt Medical Inc.
• Acessa Health Inc.
• Blue Endo
• LiNA Medical ApS
• Merit Medical Systems Inc.
• Allergan plc
• Astellas Pharma Inc.
What are the Regional Insights into the Uterine Fibroids Treatment Market?
North America was the largest region in the uterine fibroids treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine fibroids treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
